Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Columbia-Saint Mary's Cancer Care Center
mi
from
Milwaukee, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Columbia-Saint Mary's Cancer Care Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Medical Consultants, Limited
mi
from
Milwaukee, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Medical Consultants, Limited
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Marshfield Clinic - Lakeland Center
mi
from
Minocqua, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Marshfield Clinic - Lakeland Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Regional Cancer Center at Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Regional Cancer Center at Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Ministry Medical Group at Saint Mary's Hospital
mi
from
Rhinelander, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Ministry Medical Group at Saint Mary's Hospital
mi
from
Rhinelander, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Marshfield Clinic - Indianhead Center
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Vince Lombardi Cancer Clinic - Sheboygan
mi
from
Sheboygan, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Vince Lombardi Cancer Clinic - Sheboygan
mi
from
Sheboygan, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Saint Michael's Hospital Cancer Center
mi
from
Stevens Point, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Saint Michael's Hospital Cancer Center
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Aurora Medical Center
mi
from
Summit, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Aurora Medical Center
mi
from
Summit, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Vince Lombardi Cancer Clinic - Two Rivers
mi
from
Two Rivers, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Waukesha Memorial Hospital Regional Cancer Center
mi
from
Waukesha, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Waukesha Memorial Hospital Regional Cancer Center
mi
from
Waukesha, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated:  8/11/2016
Pretoria Academic Hospital
mi
from
Pretoria,
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study
Status: Enrolling
Updated: 8/11/2016
Pretoria Academic Hospital
mi
from
Pretoria,
Click here to add this to my saved trials
Randomized Clinical Trial of Pneumatic Compression Device for the Treatment of Venous Ulcers and Lymphedema
Randomized Clinical Trial of Pneumatic Compression Device for the Treatment of Venous Ulcers and Lymphedema
Status: Enrolling
Updated:  8/11/2016
New York University School of Medicine
mi
from
New York, NY
Randomized Clinical Trial of Pneumatic Compression Device for the Treatment of Venous Ulcers and Lymphedema
Randomized Clinical Trial of Pneumatic Compression Device for the Treatment of Venous Ulcers and Lymphedema
Status: Enrolling
Updated: 8/11/2016
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
Status: Enrolling
Updated:  8/15/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
Status: Enrolling
Updated: 8/15/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  8/15/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 8/15/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy
Status: Enrolling
Updated:  8/16/2016
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy
Status: Enrolling
Updated: 8/16/2016
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy
Status: Enrolling
Updated:  8/16/2016
Horizon Oncology Center BioAdvance
mi
from
Lafayette, IN
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy
Status: Enrolling
Updated: 8/16/2016
Horizon Oncology Center BioAdvance
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy
Status: Enrolling
Updated:  8/16/2016
Novartis Investigative Site
mi
from
Toulouse Cedex 9,
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy
Status: Enrolling
Updated: 8/16/2016
Novartis Investigative Site
mi
from
Toulouse Cedex 9,
Click here to add this to my saved trials
Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)
Treatment Decisions and Breast Cancer: Psychosocial Outcomes
Status: Enrolling
Updated:  9/15/2016
Kelsey Seybold
mi
from
Houston, TX
Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)
Treatment Decisions and Breast Cancer: Psychosocial Outcomes
Status: Enrolling
Updated: 9/15/2016
Kelsey Seybold
mi
from
Houston, TX
Click here to add this to my saved trials
Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)
Treatment Decisions and Breast Cancer: Psychosocial Outcomes
Status: Enrolling
Updated:  9/15/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)
Treatment Decisions and Breast Cancer: Psychosocial Outcomes
Status: Enrolling
Updated: 9/15/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects
A Phase I Study to Evaluate the Pharmacokinetic and Safety Profile of AZD9496 Following Single Dose Administration of Different Forms and Formulations in Healthy Subjects
Status: Enrolling
Updated:  11/7/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects
A Phase I Study to Evaluate the Pharmacokinetic and Safety Profile of AZD9496 Following Single Dose Administration of Different Forms and Formulations in Healthy Subjects
Status: Enrolling
Updated: 11/7/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer
A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/17/2016
Mayo Clinic
mi
from
Scottsdale, AZ
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer
A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/17/2016
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer
A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  11/17/2016
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer
A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 11/17/2016
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
IORT (Intra-operative Radiation Therapy) in Early Stage Breast Cancer
A Pilot, Single Arm, Study of the Safety and Feasibility of Single-Fraction Intraoperative Radiation Treatment (IORT) With CT-On-Rails-Guided HDR Brachytherapy for the Treatment of Early-Stage Breast Cancer
Status: Enrolling
Updated:  11/21/2016
University of Virginia Health System
mi
from
Charlottesville, VA
IORT (Intra-operative Radiation Therapy) in Early Stage Breast Cancer
A Pilot, Single Arm, Study of the Safety and Feasibility of Single-Fraction Intraoperative Radiation Treatment (IORT) With CT-On-Rails-Guided HDR Brachytherapy for the Treatment of Early-Stage Breast Cancer
Status: Enrolling
Updated: 11/21/2016
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Rural Women Connecting for Better Health
Group Phone-Based Weight Control for Rural Breast Cancer Survivors
Status: Enrolling
Updated:  11/22/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Rural Women Connecting for Better Health
Group Phone-Based Weight Control for Rural Breast Cancer Survivors
Status: Enrolling
Updated: 11/22/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Lifestyle Intervention for High Risk Cancer Survivors
Development of an Aerobic and Resistance Training Feasibility Study for a Racially and Ethnically Diverse Sample of Breast Cancer Survivors
Status: Enrolling
Updated:  12/1/2016
University of North Texas Health Science Center
mi
from
Fort Worth, TX
Lifestyle Intervention for High Risk Cancer Survivors
Development of an Aerobic and Resistance Training Feasibility Study for a Racially and Ethnically Diverse Sample of Breast Cancer Survivors
Status: Enrolling
Updated: 12/1/2016
University of North Texas Health Science Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Lifestyle Intervention for High Risk Cancer Survivors
Development of an Aerobic and Resistance Training Feasibility Study for a Racially and Ethnically Diverse Sample of Breast Cancer Survivors
Status: Enrolling
Updated:  12/1/2016
Memorial Herman Health Care System
mi
from
Houston, TX
Lifestyle Intervention for High Risk Cancer Survivors
Development of an Aerobic and Resistance Training Feasibility Study for a Racially and Ethnically Diverse Sample of Breast Cancer Survivors
Status: Enrolling
Updated: 12/1/2016
Memorial Herman Health Care System
mi
from
Houston, TX
Click here to add this to my saved trials
Lifestyle Intervention for High Risk Cancer Survivors
Development of an Aerobic and Resistance Training Feasibility Study for a Racially and Ethnically Diverse Sample of Breast Cancer Survivors
Status: Enrolling
Updated:  12/1/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Lifestyle Intervention for High Risk Cancer Survivors
Development of an Aerobic and Resistance Training Feasibility Study for a Racially and Ethnically Diverse Sample of Breast Cancer Survivors
Status: Enrolling
Updated: 12/1/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Registry of Mastectomy for Breast Cancer Risk Reduction
Registry of Mastectomy for Breast Cancer Risk Reduction
Status: Enrolling
Updated:  12/1/2016
Georgetown University Hospital
mi
from
Washington,
Registry of Mastectomy for Breast Cancer Risk Reduction
Registry of Mastectomy for Breast Cancer Risk Reduction
Status: Enrolling
Updated: 12/1/2016
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Pillars4Life Trial
Pillars4Life Randomized Control Trial
Status: Enrolling
Updated:  12/6/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Pillars4Life Trial
Pillars4Life Randomized Control Trial
Status: Enrolling
Updated: 12/6/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/14/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/14/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/14/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/14/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/14/2016
Clinical Research Facility
mi
from
Peoria, IL
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/14/2016
Clinical Research Facility
mi
from
Peoria, IL
Click here to add this to my saved trials
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/14/2016
mi
from
Leuven,
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/14/2016
mi
from
Leuven,
Click here to add this to my saved trials
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel)Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/14/2016
Abraxis BioScience, Inc.
mi
from
Raleigh, NC
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel)Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/14/2016
Abraxis BioScience, Inc.
mi
from
Raleigh, NC
Click here to add this to my saved trials
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
Evaluation of CD8+ T Cell Activation and Infiltration Into Primary Breast Tumors Following Administration of a Peptide Vaccine
Status: Enrolling
Updated:  12/15/2016
University of Virginia Health System
mi
from
Charlottesville, VA
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
Evaluation of CD8+ T Cell Activation and Infiltration Into Primary Breast Tumors Following Administration of a Peptide Vaccine
Status: Enrolling
Updated: 12/15/2016
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling
Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling (GPS)
Status: Enrolling
Updated:  12/22/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling
Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling (GPS)
Status: Enrolling
Updated: 12/22/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
Status: Enrolling
Updated:  12/28/2016
M D Anderson Cancer Center
mi
from
Houston, TX
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
Status: Enrolling
Updated: 12/28/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer
An Exploratory, Open-Label Phase I Pharmacodynamic Study of COX-2 Inhibition With Celecoxib (Celebrex) and Aromatase Activity in Breast Cancer
Status: Enrolling
Updated:  12/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer
An Exploratory, Open-Label Phase I Pharmacodynamic Study of COX-2 Inhibition With Celecoxib (Celebrex) and Aromatase Activity in Breast Cancer
Status: Enrolling
Updated: 12/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status: Enrolling
Updated:  1/3/2017
Florida Cancer Specialists - South
mi
from
Fort Myers, FL
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status: Enrolling
Updated: 1/3/2017
Florida Cancer Specialists - South
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status: Enrolling
Updated:  1/3/2017
Florida Cancer Specialists-North
mi
from
St. Petersburg, FL
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status: Enrolling
Updated: 1/3/2017
Florida Cancer Specialists-North
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status: Enrolling
Updated:  1/3/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status: Enrolling
Updated: 1/3/2017
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status: Enrolling
Updated:  1/3/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Status: Enrolling
Updated: 1/3/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Wichita NCORP
mi
from
Wichita, KA
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Wichita NCORP
mi
from
Wichita, KA
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Cancer Research Consortium of West Michigan
mi
from
Grand Rapids, MI
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Cancer Research Consortium of West Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
University of Rochester NCORP Research Base
mi
from
Rochester, NY
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
University of Rochester NCORP Research Base
mi
from
Rochester, NY
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Dayton NCORP
mi
from
Dayton, OH
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Dayton NCORP
mi
from
Dayton, OH
Click here to add this to my saved trials